What is vitamin K2 and how is it different from vitamin K1?

The vitamin K family comprises two main nutritional forms: phylloquinone (K1) and a series of menaquinones (K2). They share a naphthoquinone ring structure but differ in the length and degree of saturation of their isoprenoid side chains. Vitamin K1 is abundant in leafy green vegetables and is the primary circulating form, used predominantly by the liver for the activation of clotting factors II, VII, IX, and X. Most dietary guidelines focus on K1 because its deficiency produces the most clinically obvious consequence: impaired blood coagulation.

Vitamin K2 comprises a family of menaquinones numbered by their side chain length, from MK-4 (four isoprene units) to MK-13. In practice, MK-4 and MK-7 are the most relevant to human health and the most studied. MK-4 is found in animal products including egg yolk, butter, chicken liver, and hard cheeses, and can be synthesised in peripheral tissues from K1 via a direct conversion pathway. MK-7 is produced by fermentation and is particularly abundant in natto (fermented soybeans), certain aged cheeses, and sauerkraut.

The critical distinction between K1 and K2 is tissue distribution after absorption. K1 is rapidly cleared by the liver and contributes minimally to extrahepatic tissues. K2, particularly MK-7, circulates in lipoproteins for a much longer period and distributes effectively to bone, arterial walls, kidney, and brain. This extrahepatic distribution makes K2 the functionally dominant form for bone mineralisation and soft tissue calcium regulation.

The distinction between K1 and K2 in population diets is nutritionally significant. Most people in Western countries consume adequate K1 for clotting function but substantially suboptimal K2 for bone health purposes. Dietary K2 intake has been estimated at only 10 to 40 micrograms per day in typical Western diets, compared to the 90 to 360 micrograms tested in bone health trials, largely because fermented foods like natto are not part of most European or North American diets.

Carboxylation of osteocalcin: how K2 directs calcium into bone

The molecular mechanism by which vitamin K2 supports bone mineralisation centres on its role as a cofactor for the enzyme gamma-glutamyl carboxylase (GGCX). This enzyme converts specific glutamate (Glu) residues in target proteins to gamma-carboxyglutamate (Gla) residues, a post-translational modification that gives these proteins the ability to bind calcium ions and calcium-containing crystal surfaces including hydroxyapatite.

The most important Gla protein in the bone context is osteocalcin (also called bone Gla protein or BGP). Osteocalcin is synthesised by osteoblasts and odontoblasts and, after gamma-carboxylation by K2-dependent GGCX, is secreted into the extracellular matrix where it binds to hydroxyapatite crystals in bone and dentin. Carboxylated osteocalcin serves as a scaffold protein that organises hydroxyapatite crystal growth and co-ordinates mineral deposition within the collagen matrix, a function critical to producing bone and dentin with normal density and fracture resistance.

When K2 status is insufficient, gamma-carboxylation is incomplete and a higher proportion of circulating and tissue osteocalcin remains in the under-carboxylated (ucOC) form. Under-carboxylated osteocalcin cannot bind hydroxyapatite effectively, meaning that even if calcium and phosphate are present in adequate supply, osteocalcin's scaffolding function is compromised. Measuring ucOC/total osteocalcin ratio is a sensitive marker of functional K2 status that is more specific to bone metabolism than other K2 biomarkers. Studies published in the Journal of Bone and Mineral Research have consistently found that ucOC ratio correlates inversely with bone mineral density at multiple skeletal sites and correlates positively with fracture risk.

Osteocalcin is also produced by odontoblasts, the cells that form dentin. While the direct evidence for K2's role in dentin mineralisation in humans is more limited than for skeletal bone (largely because dentin cannot be biopsied ethically in living adults), animal studies consistently show that K2 deficiency produces dentin defects including reduced mineralisation density and abnormal tubule structure. The implication is that K2 is as important for the mineralisation of the dentin matrix as it is for alveolar bone.

Matrix GLA protein and the prevention of soft tissue calcification

The second major Gla protein relevant to oral and systemic health is matrix GLA protein (MGP), produced by vascular smooth muscle cells, chondrocytes, and osteoblasts. MGP is one of the most potent known inhibitors of soft tissue calcification: it binds calcium crystals in arterial walls and other soft tissues and prevents their growth. Under-carboxylated MGP (dp-ucMGP) is a marker of K2 deficiency specifically in vascular and soft tissue contexts, and elevated dp-ucMGP is strongly associated with arterial calcification and cardiovascular mortality in observational studies.

In the oral context, MGP is expressed in the periodontal ligament and is thought to prevent pathological calcification of the ligament fibres, which would compromise their ability to flex and absorb mechanical forces during chewing. Calcification of the periodontal ligament is associated with hypercementosis and ankylosis, both of which complicate tooth extraction and implant placement. Whether K2 deficiency contributes to periodontal ligament calcification in clinical practice has not been systematically studied, but the mechanistic pathway is clear.

The systemic anti-calcification function of K2-activated MGP also connects to cardiovascular health, which itself has well-documented bidirectional links to periodontal disease. Patients with significant cardiovascular calcification (a marker of systemic K2 deficiency) frequently also have periodontal disease, and patients with severe periodontitis have higher rates of cardiovascular events. Whether K2 deficiency represents a shared mechanism linking these two conditions through impaired MGP carboxylation has not been definitively tested but represents an active research hypothesis.

K2 and alveolar bone: the periodontal connection

Alveolar bone is the most metabolically active bone in the skeleton. It remodels rapidly in response to mechanical forces from chewing, orthodontic movement, and inflammatory signals from the periodontal tissue. Because of this rapid turnover, alveolar bone is among the most sensitive tissues to changes in systemic mineral metabolism and vitamin status.

A 2020 case-control study published in Clinical Oral Investigations measured serum osteocalcin carboxylation status in 45 patients with moderate to severe chronic periodontitis and 40 periodontally healthy controls. Patients with periodontitis showed significantly higher ucOC/total osteocalcin ratios (indicating functional K2 insufficiency) and significantly lower carboxylated osteocalcin concentrations. After adjustment for age, sex, smoking, and body mass index, the ucOC ratio remained an independent predictor of both probing pocket depth and alveolar bone loss measured on standardised radiographs. The association was strongest for patients with generalised Stage III or IV periodontitis.

This is observational evidence and does not establish whether K2 deficiency caused the periodontitis-associated bone loss or whether the inflammatory environment of periodontitis depleted K2 through increased tissue turnover and consumption. Both directions are biologically plausible. Osteoclast activity in active periodontitis is intense, and the osteoblastic repair phase following professional treatment requires high levels of carboxylated osteocalcin to complete mineralisation of newly formed bone matrix. K2 insufficiency during this repair phase could slow or reduce the quality of the alveolar bone regenerated after treatment.

Research published in the Journal of Periodontology in 2022 examined whether K2-MK-7 supplementation (180 micrograms per day for 12 weeks) as an adjunct to scaling and root planing improved alveolar bone density measurements compared to scaling alone in patients with Stage II chronic periodontitis. The K2 group showed a statistically significant improvement in digital subtraction radiography bone density scores at 12 weeks, along with greater reductions in pocket depth and bleeding on probing. This is one of the first interventional studies to directly measure alveolar bone density as a K2 supplementation outcome, and its findings warrant replication in larger, multicentre trials.

Vitamin K2 and vitamin D3: why they work best together

The synergy between vitamin D3 and vitamin K2 has become one of the most discussed interactions in nutritional medicine, and for good reason. Their mechanisms interlock at the point of calcium regulation and bone protein function.

Vitamin D3 (cholecalciferol), after hepatic conversion to 25-hydroxyvitamin D and renal conversion to the active form 1,25-dihydroxyvitamin D (calcitriol), has two primary effects on calcium and bone metabolism: it stimulates active calcium absorption from the intestine (via upregulation of the TRPV6 calcium channel and calbindin D9k), and it directly upregulates the transcription of osteocalcin and other Gla proteins in osteoblasts. The second effect means that higher vitamin D status drives higher osteocalcin production, increasing the demand for K2-dependent carboxylation.

If K2 status is insufficient relative to D3-driven osteocalcin production, the excess under-carboxylated osteocalcin circulates without the ability to bind bone mineral and may compete with carboxylated osteocalcin for mineralisation scaffolding sites. Some researchers have proposed that high-dose vitamin D supplementation without adequate K2 co-supplementation could theoretically worsen mineralisation quality, though this remains debated and has not been definitively demonstrated in human trials. The precautionary approach supported by mechanistic evidence is to ensure adequate K2 status whenever supplementing with significant doses of vitamin D3.

A three-year randomised trial published in Osteoporosis International tested D3 alone, K2-MK-7 alone, D3 plus K2-MK-7, and placebo in 244 postmenopausal women. The combination group showed the greatest increase in bone mineral density at the femoral neck and lumbar spine at 3 years, outperforming either supplement alone. While this study focused on skeletal sites rather than alveolar bone specifically, the principle that D3 and K2 are synergistic for bone mineral quality is well-supported by the available human trial evidence.

MK-4 versus MK-7: which form matters for dental and bone health?

The pharmacokinetic differences between MK-4 and MK-7 have direct implications for supplementation strategy. MK-7, with its longer isoprenoid side chain, is more lipophilic and integrates more effectively into LDL and HDL lipoprotein particles, which serve as the primary transport vehicle for K2 in the circulation. The result is a plasma half-life of approximately 68 to 72 hours for MK-7, compared to approximately 2 to 4 hours for MK-4 and 1 to 2 hours for K1. This extended half-life means a single daily dose of 90 to 200 micrograms of MK-7 maintains elevated and relatively stable plasma K2 concentrations throughout the 24-hour cycle.

MK-4 has been tested in Japanese clinical trials for osteoporosis treatment at doses of 45,000 micrograms (45 mg) three times daily, a dose roughly 1,500 times higher than the MK-7 doses that produce equivalent osteocalcin carboxylation. At pharmacological MK-4 doses, reductions in fracture risk have been demonstrated in Japanese postmenopausal women, which influenced Japanese regulatory approval of MK-4 as an osteoporosis treatment at those doses. However, the very high doses required make MK-4 impractical as a dietary supplement at accessible price points, and the European supplement market predominantly uses MK-7 for this reason.

For supplementation targeting alveolar bone health, MK-7 at 90 to 200 micrograms per day represents the most evidence-based approach. The dose range overlaps with the 180 microgram per day dose used in the 2022 Journal of Periodontology trial and with the 90 to 360 microgram per day range used in the majority of bone mineral density intervention studies showing positive results.

Dietary sources of K2 and supplementation context

Natto, a traditional Japanese fermented soybean dish, is by far the richest dietary source of K2-MK-7, containing approximately 1,000 micrograms per 100 g serving. This single food source explains much of the consistently favourable bone health data from Japan, where natto consumption correlates geographically with lower hip fracture rates even within the country.

For those outside Japan or not accustomed to natto's strong flavour and fermented texture, other fermented foods provide meaningful but lower MK-7 concentrations. Hard cheeses (particularly Gouda and Edam) contain 50 to 75 micrograms of K2 per 100 g, predominantly as MK-7 and MK-9. Brie and Camembert provide approximately 50 micrograms per 100 g. Soft cheeses and fresh cheeses generally contain much less. Sauerkraut provides 4 to 10 micrograms per 100 g, and traditional cheese-making processes appear to be the key factor determining K2 content.

MK-4 is found in egg yolk (approximately 25 micrograms per yolk), chicken liver (30 to 50 micrograms per 100 g), and butter (around 15 micrograms per 100 g). These foods contribute to K2 status but their short half-life means their bone health contribution per microgram is substantially lower than from MK-7 sources.

For individuals without reliable dietary K2 sources, supplementation with 100 to 200 micrograms of MK-7 daily represents a straightforward and safe approach. K2 has no established upper tolerable intake level in most regulatory systems (the EU EFSA has not set a tolerable upper intake due to absence of adverse effects even at high doses), and no serious adverse effects have been reported in clinical trials at the doses studied for bone health.

Building a complete oral bone health strategy around K2

Vitamin K2 sits within a nutrient web for oral bone health that includes calcium, phosphorus, magnesium, vitamin D3, and several trace minerals. For the alveolar bone and periodontal ligament that keep teeth anchored, K2 provides the activation step that allows the entire mineralisation machinery to function at full capacity.

A practical framework for supporting oral bone health through nutrition includes: ensuring adequate calcium intake from dairy or fortified foods (1,000 to 1,200 mg per day), maintaining serum 25-hydroxyvitamin D above 50 nmol/L (ideally 75 to 100 nmol/L), supplementing with MK-7 at 100 to 200 micrograms per day if dietary fermented food intake is low, and ensuring adequate magnesium (see our article on magnesium and teeth for context on how magnesium regulates crystal growth and alkaline phosphatase function).

This systemic nutritional strategy supports the bone and collagen infrastructure that holds teeth in place. The enamel surface of those teeth requires a different and complementary intervention: direct mineral replenishment through nano-hydroxyapatite or fluoride at the tooth surface. Enamel is approximately 97% hydroxyapatite and cannot be reached by systemic mineralisation pathways; it can only be remineralised by surface contact with supersaturated mineral solutions or nano-particulate mineral carriers. Minvelle remineralising gum provides this surface mineral delivery through nano-hydroxyapatite approved by the European SCCS in 2023, alongside xylitol for microbiome modulation and Chios mastic resin for antimicrobial and anti-inflammatory benefits.

Zinc also deserves mention as a micronutrient that works alongside K2 in supporting oral bone integrity. Zinc activates alkaline phosphatase, is required for collagen cross-linking in bone matrix, and supports osteoblast differentiation. Its role is covered in detail in our dedicated article on zinc deficiency and oral health.

Frequently asked questions